Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, China

Yan Ma, Qing-nan Xu, Feng-li Wang, Xiao-man Ma, Xiao-yan Wang, Xiao-guo Zhang*, Zhong-fa Zhang**

Department of Respiratory Medicine, Jinan Infectious Diseases Hospital, Shandong University, 22029# Jing-Shi Road, Jinan, 250021, China

ABSTRACT

Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously and rapidly circulating at present. Asymptomatic patients have been proven to be contagious and thus pose a significant infection control challenge. Here we describe the characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, Shandong province, China. A total of 47 patients with confirmed COVID-19 were recruited. Among them, 11 patients were categorized as asymptomatic cases. We found that the asymptomatic patients in Jinan were relatively young and were mainly clustered cases. The laboratory indicators and lung lesion on chest CT were mild. No special factors were found accounting for the presence or absence of symptoms. The presence of asymptomatic patients increased the difficulty of screening. It is necessary to strengthen the identification of such patients in the future.

© 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Since an outbreak of COVID-19 in Wuhan and related regions in Hubei province [1–5], an increasing number of exported cases have been confirmed in other provinces of China and multiple countries around the world [6–8]. As of March 10, 2020, more than 110,000 confirmed cases of COVID-19 have been reported in 110 countries [9]. The most common clinical manifestation of the disease is fever, fatigue, and dry cough and some patients may present with nasal congestion, runny nose, and diarrhea. In some cases, dyspnea usually occurs one week after the disease onset and some patients can rapidly progress to septic shock, acute respiratory distress syndrome (ARDS), refractory metabolic acidosis, and coagulation disorders [10,11]. As the situation progressed over time, more and more asymptomatic individuals were identified due to increased surveillance and contact screening [12]. Those asymptomatic cases may play a role in the transmission and thus pose a significant infection control challenge. To best of our knowledge, so far, there is no special paper describing the features of these patients. Here we report the characteristics of asymptomatic patients with confirmed SARS-CoV-2 infection admitted to Jinan infectious disease hospital, Shandong University. The hospital is the only one designated medical institution for the hospitalization of confirmed patients with COVID-19 in Jinan, capital of Shandong province, China. Furthermore, we compared the features between asymptomatic and symptomatic cases to determine whether there exist factors accounting for the presence or absence of symptoms.

1. Patients and method

1.1. Patients involvement

All the inpatients with COVID-19 confirmed by pharyngeal swab COVID-19 nucleic acid test from January 23 to March 10 in Jinan infectious disease hospital, Shandong University were included in this study. The patients were diagnosed and treated according to the “Diagnosis and Treatment Guideline for COVID-19” distributed by Chinese National Health Commission [10].

1.2. Data collection

The medical records of patients were analyzed by the research team. Demographic information, epidemiological history, clinical characteristics, laboratory findings, chest computed tomographic (CT) scan and outcome of each patient were obtained from the electronic medical record system of Jinan infectious disease hospital. Laboratory test results included a complete blood count,
serum biochemistry, coagulation function, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and myocardial enzyme spectrum. The data for some patients were missing due to the absence of tests or delayed results. Clinical outcomes were followed up until 24:00, March 10, 2020. The study was approved by the Ethics Committee of Jinan infectious disease hospital, Shandong University, with a waiver of written informed consent because of the retrospective nature of the study.

1.3. Statistical analysis

The continuous variables were expressed as medians with ranges and were compared with the Mann–Whitney U test. The categorical variables were presented as frequencies and percentages and were analyzed by the $\chi^2$ test. All statistical analyses were done with SPSS software version 19.0, and a $P$ value less than 0.05 was considered statistically significant.

2. Results

2.1. Baseline characteristics of asymptomatic patients in the study

A total of 47 patients were diagnosed as COVID-19 from January 23 to March 10, with 11 (23.4%) patients categorized into asymptomatic group and 36 (76.6%) patients categorized into symptomatic group. Among asymptomatic patients, 6 (54.5%) patients were men and 5 patients (45.5%) were women. The median age for the patients was 23 years, ranging from 1 to 60 years old; of them, 5 (45.5%) were children and 6 were adults. 3 (27.3%) patients came from Wuhan, Hubei Province of China. 8 (72.7%) patients were residents of Jinan, 7 (63.6%) of which contacted with confirmed cases. Among 11 asymptomatic patients, 9 (81.8%) were cluster cases, 8 (72.7%) of which were family cluster cases and 1 (9.1%) were other cluster cases. Compared with symptomatic patients, asymptomatic patients were relatively younger (median age, 23 years vs 35.5 years), and were more likely cluster cases (81.8% vs 72.2%), but there was no statistical significance between the two groups. The detailed baseline characteristics of the study population are summarized in Table 1.

2.2. Clinical characteristics of asymptomatic patients in the study

For 11 asymptomatic patients, 5 were mild cases and 6 were common cases; the median time from admission to negative conversion of viral RNA was 10 days, ranging from 3 days to 34 days; and the median time of hospital stay was 14 days, ranging from 10 days to 30 days. Compared with symptomatic patients, the hospital stay of asymptomatic patients is significantly shorter (14 days vs 22.5 days, $P = 0.004$), while the diagnostic classification and time of negative viral RNA conversion did not differ between two groups. For the 36 symptomatic patients, the most common symptoms were fever (28, 77.8%), followed by dry cough (17, 47.2%), expectoration (4, 11.1%), fatigue (4, 11.1%), sore throat (4, 11.1%), myalgia (4, 11.1%), headache (2, 5.6%), and coryza (1, 2.8%). The detailed clinical characteristics were found in Tables 2 and 3.

2.3. Laboratory and radiologic findings of asymptomatic patients in the study

The blood cell test results showed that 27.3% (3/11) asymptomatic patients had decreased white blood cell and 36.4% (4/11) had increased lymphocyte count. Increased or decreased platelet counts were also found in these patients. Levels of lactate dehydrogenase and creatine kinase-MB increased in about half of the patients. Other laboratory findings in the asymptomatic patients included higher or lower levels of fibrinogen, higher levels of D-dimer, C-reactive protein and ESR. Although there were many laboratory abnormalities in asymptomatic patients, compared with symptomatic patients, most of the indicators were not statistically significant.

Abnormalities on chest computed tomograms (CT) were detected in 7 asymptomatic patients (63.6%) (Table 4), of which 4 (36.4%) showed bilateral involvement and 3 (27.3%) showed unilateral involvement. Compared with symptomatic patients, asymptomatic patients had fewer lung CT lesions (63.6% vs 83.3%), and there was no statistical difference between the two groups. The typical chest CT findings of these patients were unilateral or bilateral multiple ground-glass opacities or consolidation. Fig. 1 showed representative lung images of an asymptomatic patient in which lesions developed in multiple lobes, most of which were subpleural ground-glass opacity co-existed with consolidation. Fig. 2 showed dynamic changes of the chest CT of an asymptomatic patient obtained on February 5(A), February 8(B), February 14(C) and February 19(D).

2.4. Treatment and clinical outcomes

All patients received antiviral treatment, including lopinavir/ritonavir tablets, arbidol, and inhalation of recombinant human interferon. The duration of antiviral treatment was 10–15 days. As of 24:00, March 10, 2020, 100% (36/36) symptomatic patients and 81.8% (9/11) asymptomatic patients have been discharged, and the remaining 2 patients still have positive nucleic acid test results.

3. Discussion

The current coronavirus outbreak in China and other countries is the third epidemic caused by coronavirus in the 21st century, already surpassing SARS and MERS in the number of individuals infected [6]. The COVID-19 can present a variety of manifestations ranging from no symptoms or mild disease to severe pneumonia or multi-organ failure. It is expected that early in the development of an outbreak, severe cases are recognized first and then less severe (mild or asymptomatic) cases are detected with increasing surveillance. The occurrence of asymptomatic individuals increased the difficulty of screening, helped spread the disease, therefore, posed a significant public health issue.

In our study, a total of 47 patients were diagnosed as COVID-19 from January 23 to March 10, of which 11 (23.4%) patients had no
The asymptomatic proportion (23.4%) is higher than the data (17.9%) reported by Kenji Mizumoto [13]. Among 11 asymptomatic patients, 9 (81.9%) were cluster cases, 8 (72.7%) of which were family cluster cases and 1 (9.1%) were other cluster cases. The presence of cluster cases strongly suggested the need to isolate patients and quarantine for close contacts, especially those family close contacts. The median age of the asymptomatic patients was 23 years old, which is younger than the symptomatic patients (35.5 years), while there was no statistical significance between the two groups. For the 36 symptomatic patients, Fever (77.8%), dry cough (47.2%), expectoration (11.1%), fatigue (11.1%), sore throat (11.1%), myalgia (11.1%) were the most common symptoms, which was consistent with previous studies [3, 5, 14].

Laboratory findings of the asymptomatic patients showed that some patients might have abnormalities in indicators such as blood cell count, fibrinogen, D-dimmer, C-reactive protein, ESR and myocardial enzymes. Compared with symptomatic patients, most of the laboratory test results were not statistically significant. It is worth noting that creatine kinase-MB was significantly higher in the asymptomatic group than in the symptomatic group (P = 0.020). Future research is needed to expand the sample to clarify that this indicator does indeed differ between the two groups. Although some asymptomatic patients’ laboratory indicators were abnormal, the damage was minor and soon returned.

### Table 2
Clinical characteristics of patients infected with SARS-CoV-2.

| Item                      | All cases | Asymptomatic | Symptomatic | P-value |
|---------------------------|-----------|--------------|-------------|---------|
| No. (%)                   | 47        | 11(23.4)     | 36(76.6)    |         |
| Diagnostic classification(N, %) |         |              |             | 0.077   |
| Mild case                  | 10(21.3)  | 5(45.5)      | 5(13.9)     |         |
| Common case                | 36(76.6)  | 6(54.5)      | 30(83.3)    |         |
| Severe case                | 1(2.1)    | 0(0.0)       | 1(2.8)      |         |
| Time from admission to negative conversion of viral RNA (days, median, range) | | | | 0.182 |
|                          | 13.5(3–39) | 10(3–34)     | 16(5–39)    |         |
| Time of hospital stay (days, median, range) | | | | 0.004 |
|                          | 22(10–44)  | 14(10–30)    | 22.5(12–44) |         |
| Outcome(N, %)             |           |              |             | 0.051   |
| Discharge                 | 45(95.7)  | 9(81.8)      | 36(100)     |         |
| Hospitalization           | 2(4.3)    | 2(18.2)      | 0(0.0)      |         |

### Table 3
Symptoms of patients infected with SARS-CoV-2.

| Items                    | N | Percentage, % |
|--------------------------|---|---------------|
| No. of patients          | 36 | 100           |
| Symptoms                 |   |               |
| Fever                    | 28 | 77.8          |
| Dry cough                | 17 | 47.2          |
| Expectoration            | 4  | 11.1          |
| Fatigue                  | 4  | 11.1          |
| Sore throat              | 4  | 11.1          |
| Myalgia                  | 4  | 11.1          |
| Headache                 | 2  | 5.6           |
| Coryza                   | 1  | 2.8           |
| Nausea and vomiting      | 0  | 0.0           |
| Diarrhea                 | 0  | 0.0           |

### Table 4
Laboratory and radiological findings of patients infected with SARS-CoV-2.

| Items                      | All cases(n) | Asymptomatic (n, %) | Symptomatic (n, %) | P-value |
|----------------------------|--------------|---------------------|--------------------|---------|
| No. of patients            | 47           | 11(23.4)            | 36(76.6)           |         |
| White blood cell count (×10^9/L, normal range 4–10) | | | | 1.000 |
| Decreased                 | 47           | 3(27.3)             | 11(30.6)           |         |
| Neutrophil count (×10^9/L, normal range 2–7) | 47 | 1(9.1)       | 9(25.0)            | 0.166   |
| Decreased                 | 47           | 1(9.1)              | 0(0.0)             |         |
| Lymphocyte count (×10^9/L, normal range 0.8–4) | 47 | 0(0.0)       | 4(11.1)            | 0.011   |
| Decreased                 | 47           | 4(36.4)             | 1(2.8)             |         |
| Platelet count (×10^9/L, normal range 100–300) | 47 | 1(9.1)       | 1(2.8)             | 0.151   |
| Increased                 | 47           | 2(18.2)             | 2(5.6)             |         |
| Fibrinogen (g/L, normal range 2–4) | 43 | 2(22.2)     | 1(2.9)             | 0.122   |
| Decreased                 | 43           | 1(11.1)             | 11(32.4)           |         |
| Increased                 | 43           | 11(11.1)            | 4(11.8)            |         |
| D-dimer (mg/ml, normal range 0–0.5) | 43 | 3(27.3)     | 14(38.9)           | 0.722   |
| Increased                 | 47           | 14(38.9)            | 8(22.9)            |         |
| C-reactive protein (mg/L, normal range 0.068–8.2) | 47 | 1(9.1)       | 5(14.3)            | 0.285   |
| Increased                 | 47           | 11(11.1)            | 12(32.4)           |         |
| Erythrocyte sedimentation rate (mm/H, normal range 0–15) | 47 | 14(38.9) | 0.137 |
| Increased                 | 47           | 14(38.9)            | 8(22.9)            |         |
| Lactate dehydrogenase (U/L, normal range 109–245) | 46 | 5(45.5)     | 0.020              |
| Increased                 | 46           | 5(45.5)             | 8(22.9)            |         |
| Creatine kinase-MB (U/L, normal range 7–25) | 46 | 6(54.5)     | 0.659              |
| Increased                 | 37           | 7(36.6)             | 30(83.3)           |         |
| Bilateral distribution of patchy shadows or ground glass opacity | 4(36.4) | 2(18.2)     |         |
| Unilateral distribution of patchy shadows or ground glass opacity | 3(27.3) | 9(25.0)     |         |
7 asymptomatic patients (63.6%) were detected lung abnormalities on chest CT. Compared with symptomatic patients, asymptomatic patients had fewer lung CT lesions (63.6% vs 83.3%), and there was also no statistical difference between the two groups. All of the laboratory test results and radiologic findings showed the patients experienced relatively mild illness, which was further evidenced by the short hospital stay of asymptomatic patients ($P = 0.004$). All the patients’ treatment regimen were produced according to the diagnostic and treatment guidelines for COVID-19 issued by the National Health Commission of the People’s Republic of China. As of 24:00, March 10, 2020, 100% (36/36) symptomatic patients and 81.8% (9/11) asymptomatic patients have been discharged. 2 asymptomatic patients still hospitalized for nucleic acid positive.

Asymptomatic patients have been proven to be contagious and thus pose a significant infection control challenge [15–17]. Initially, we hoped to find whether there existed factors accounting for the presence or absence of symptoms which could help us to screen the asymptomatic individuals, and further help to control the disease. In our study, we compared the characteristics of asymptomatic and symptomatic cases and have not found effective indicators to meet our requirements. Therefore, the symptomatic patients should be given timely isolation and treatment, and relevant contacts should be tracked and quarantined as soon as possible. The timely diagnosis, isolation and treatment of these asymptomatic patients will help control the further spread of SARS-CoV-2. Future studies should investigate viral loads and viral dynamics of asymptomatic patients, and examine whether they are different from symptomatic patients. Such researches will enhance the understanding of the pathogenesis of the new emerging virus and would help to control the disease early.

Our study has some limitations. First, our research samples are relatively small and it was difficult to get a full picture of the spectrum of the disease. Second, our asymptomatic patients may truly have no symptoms, or they may not feel it because the symptoms are not obvious. Third, some indicators related to patient’s viral loads or immunity, such as CD4$^+$ and CD8$^+$ cells, are not involved in this study. All of those can lead to a biased understanding of the disease.

In conclusion, our study showed the clinical characteristics of asymptomatic patients with COVID-19 in Jinan, China. The patients were relatively young and were mainly clustered cases. The laboratory indicators and lung lesion on chest CT were mild. No special factors were found accounting for the presence or absence of

Fig. 1. Representative lung images of an asymptomatic patient in which lesions developed in multiple lobes, most of which were subpleural ground-glass opacity co-existed with consolidation.
symptoms. The presence of asymptomatic patients increased the difficulty of screening. It is necessary to strengthen the identification of such patients in the future.

Declaration of Competing Interest

None of the authors have any conflict of interest to declare.

Acknowledgments

The present study was supported by a grant (number 202001003) from Jinan Science and Technology Bureau, Jinan China.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.

[2] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–9.

[3] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020. https://doi.org/10.1111/all.14238.

[4] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020;133(9):1025–31.

[5] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[6] Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA 2020;323(11):1092–3.

[7] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020 Feb 19;368:m606. https://doi.org/10.1136/bmj.m606.

[8] Ki M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health 2020;42:e2020007. https://doi.org/10.4178/eph.e2020007.

[9] WHO. Coronavirus disease 2019 (COVID-19) situation report – 50. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200310-sitrep-50-covid-19.pdf?sfvrsn=55e904fb_2.

[10] National Health Commission of the PRC. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version5). Available from: http://www.nhc.gov.cn/zycwjyk/gwyj/202002/2b909894ac9ba4204a79db59b8912d4440.shtml.

[11] Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020. https://doi.org/10.1007/s11606-020-05762-w.

[12] Lin C, Ding Y, Xie B, Sun Z, Li X, Chen Z, et al. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease. Clin Imag 2020 Feb 22;63:7–9. https://doi.org/10.1016/j.clinimag.2020.02.008 [Epub ahead of print].
[13] Mizumoto Kenji KK, Alexander Zarebski, Gerardo Chowell. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020;25:pii--2000180.

[14] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.

[15] Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323(14):1406–7.

[16] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020;395:514–23.

[17] Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970–1.